financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Maintains Hold Opinion On Shares Of Ciena Corporation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Maintains Hold Opinion On Shares Of Ciena Corporation
Jun 9, 2024 10:05 PM

12:35 AM EDT, 06/10/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our 12-month target price by $5 to $50, 17.4x our FY 25 (Oct.) EPS estimate, a discount to its five-year forward average P/E at 18.6x, reflecting our slower growth outlook and challenging market conditions. We lower our FY 24 EPS estimate by $0.32 to $1.97 and FY 25's by $0.31 to $2.88. CIEN reported Apr-Q operating EPS of $0.27 vs $0.74, $0.16 above the consensus. Apr-Q revenue decreased 19.6%, driven by a 28.6% drop in Optical Networking, an 11.0% decline in Routing and Switching, and a 30.1% fall in Blue Planet Automation Software and Services, partially offset by 23.1% growth in Platform Software and Services. In the near term, while CIEN is seeing signs of improvement, the recovery of service provider order patterns is still slower than initially expected as they continue to absorb and deploy large amounts of their inventory.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Maintains Hold Opinion On Shares Of Arm Holdings Plc
Research Alert: CFRA Maintains Hold Opinion On Shares Of Arm Holdings Plc
May 9, 2024
08:05 AM EDT, 05/09/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We adjust our 12-month target to $120 from $140, on a lower revised peer-premium P/E of 64.8x our CY 25 EPS estimate, warranted given our view of growth prospects. We...
Research Alert: CFRA Lowers Opinion On Shares Of United Parks & Resorts Inc. To Hold From Buy
Research Alert: CFRA Lowers Opinion On Shares Of United Parks & Resorts Inc. To Hold From Buy
May 8, 2024
02:35 AM EDT, 05/09/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target to $56 from $61, on 2024 EV/EBITDA of 7.3x, near the low-end of PRKS's long-term trading range of 7x-12x. We lift our 2024 EPS to...
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Trade Desk, Inc.
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Trade Desk, Inc.
May 8, 2024
12:45 AM EDT, 05/09/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month target at $100, on a P/E of 53.5x our '25 view, above peers but within its 10-year historical forward average. We keep our above consensus '24...
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
May 8, 2024
Treating America's obesity epidemic is turning into big business. Two pharmaceutical companies, Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) , are leading the weight-loss revolution with a new class of drugs known as GLP-1 agonists. Surging revenue and growing excitement has led some analysts to compare the success of GLP-1 drugs in the health and wellness...
Copyright 2023-2026 - www.financetom.com All Rights Reserved